In vitro effect of photodynamic therapy with different lights and combined or uncombined with chlorhexidine on candida spp.

Pérez-Laguna V. ; Barrena-López Y. ; Gilaberte Y. (Universidad de Zaragoza) ; Rezusta A. (Universidad de Zaragoza)

Resumen: Candidiasis is very common and complicated to treat in some cases due to increased resistance to antifungals. Antimicrobial photodynamic therapy (aPDT) is a promising alternative treatment. It is based on the principle that light of a specific wavelength activates a photosensitizer molecule resulting in the generation of reactive oxygen species that are able to kill pathogens. The aim here is the in vitro photoinactivation of three strains of Candida spp., Candida albicans ATCC 10231, Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258, using aPDT with different sources of irradiation and the photosensitizer methylene blue (MB), alone or in combination with chlorhexidine (CHX). Irradiation was carried out at a fluence of 18 J/cm2 with a light-emitting diode (LED) lamp emitting in red (625 nm) or a white metal halide lamp (WMH) that emits at broad-spectrum white light (420–700 nm). After the photodynamic treatment, the antimicrobial effect is evaluated by counting colony forming units (CFU). MB-aPDT produces a 6 log10 reduction in the number of CFU/100 µL of Candida spp., and the combination with CHX enhances the effect of photoinactivation (effect achieved with lower concentration of MB). Both lamps have similar efficiencies, but the WMH lamp is slightly more efficient. This work opens the doors to a possible clinical application of the combination for resistant or persistent forms of Candida infections.

Idioma: Inglés

DOI: 10.3390/pharmaceutics13081176

Año: 2021

Publicado en: Pharmaceutics 13, 8 (2021), 1176 [13 pp.]
ISSN: 1999-4923

Factor impacto JCR: 6.525 (2021)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 39 / 279 = 0.14 (2021) - Q1 - T1

Factor impacto CITESCORE: 6.0 - Pharmacology, Toxicology and Pharmaceutics (Q2)

Factor impacto SCIMAGO: 0.922 - Pharmaceutical Science (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B10_17R
Financiación: info:eu-repo/grantAgreement/ES/DGA/B18_17R
Financiación: info:eu-repo/grantAgreement/ES/MINECO/CTQ2013-48767-C3-2-R

Tipo y forma: Article (Published version)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)